Mettler-Toledo International Inc. to Present at Upcoming Investor Conferences Share COLUMBUS, Ohio--(BUSINESS WIRE)--Mettler-Toledo International Inc. (NYSE: MTD) today announced it will present at the 8 Annual Evercore Healthcare Conference on Tuesday, December 2 at 9:10 a.m. EST, and at the Citi 2025 Global Healthcare Conference on Wednesday, December 3 at 10:30 a.m. EST. A live webcast of the presentations will be available on the Company's investor relations website at investor.mt.com. METTLER TOLEDO (N ...

Core Insights - Mettler-Toledo reported revenue of $1.03 billion for Q3 2025, a year-over-year increase of 7.9% and a surprise of +3.84% over the Zacks Consensus Estimate of $991.67 million [1] - The company's EPS for the quarter was $11.15, up from $10.21 a year ago, exceeding the consensus estimate of $10.62 by +4.99% [1] Revenue Breakdown - Net Sales- Products reached $766.65 million, surpassing the average estimate of $748.2 million, with a year-over-year change of +7.1% [4] - Net Sales- Service totaled $263.05 million, exceeding the average estimate of $242.5 million, reflecting a year-over-year increase of +10.1% [4] - Net Sales- Retail amounted to $58.54 million, above the average estimate of $51.8 million, with a year-over-year change of +8% [4] - Net Sales- Industrial were $406.4 million, compared to the average estimate of $378.99 million, representing a year-over-year increase of +11.2% [4] - Net Sales- Laboratory reached $564.77 million, slightly above the average estimate of $559.88 million, with a year-over-year change of +5.6% [4] Stock Performance - Mettler-Toledo shares have returned +10.1% over the past month, contrasting with the Zacks S&P 500 composite's -0.2% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Mettler-Toledo reported Q3 CY2025 results with revenue of $1.03 billion, exceeding market expectations by 7.9% year on year [1][6] - The company's Q4 CY2025 revenue guidance of $1.08 billion is 2.4% below analysts' estimates [1][6] - Non-GAAP profit per share was $11.15, which is 4.5% above analysts' consensus estimates [1][6] Revenue and Earnings Performance - Revenue of $1.03 billion compared to analyst estimates of $997.5 million, representing a 7.9% year-on-year growth [6] - Adjusted EPS of $11.15 versus analyst estimates of $10.67, a 4.5% beat [6] - Adjusted EBITDA was $308.1 million, slightly below analyst estimates of $311.5 million, with a margin of 29.9% [6] Management Commentary - Management attributed performance to strong growth in Industrial and Laboratory segments, particularly in the Americas [3] - The CEO highlighted the Spinnaker sales and marketing program and new product launches as key growth drivers [3] - Ongoing margin pressures were acknowledged due to tariffs and increased investments in sales and marketing [5] Future Outlook - Management's guidance reflects caution due to global economic uncertainty and trade disputes [4] - The company aims to mitigate tariff impacts through price realization and supply chain optimization [4] - Mettler-Toledo is focusing on opportunities in automation, digitalization, and near-shoring trends [4] Key Financial Metrics - Operating margin decreased to 28.2% from 29.2% in the same quarter last year [6] - Organic revenue growth was 6% year on year, surpassing analyst estimates of 3.4% [6] - Market capitalization stands at $29.65 billion [6]

Core Insights - Mettler-Toledo International (MTD) reported third-quarter 2025 adjusted earnings of $11.15 per share, exceeding the Zacks Consensus Estimate by 4.99%, with a year-over-year increase of 9.2% [1][8] - Net sales reached $1.03 billion, surpassing the Zacks Consensus Estimate by 3.84%, although it represented an 8% decline on a reported basis and a 6% decline on a local currency basis compared to the previous year [1][8] Revenue Breakdown - MTD's revenues are categorized into three segments: Laboratory ($565 million, 54.9% of net sales), Industrial ($406 million, 39.4% of net sales), and Food Retail ($59 million, 5.7% of net sales) [2] - Year-over-year growth in local currency for the segments was 4% for Laboratory, 9% for Industrial, and 5% for Food Retail [2] Geographic Sales Performance - Total sales from the Americas, Europe, and Asia/Rest of the World were $432 million (41.9% of net sales), $293 million (28.4%), and $305 million (29.6%), respectively [3] - Sales in the Americas and Asia/Rest of the World increased by 4% and 1% year-over-year in local currency, while Europe sales remained unchanged [3] Operating Metrics - The gross margin for Q3 2025 was 59.2%, a contraction of 80 basis points year-over-year [4] - Research & Development (R&D) expenses were $51.1 million, up 8.5% year-over-year, while Selling, General & Administrative (SG&A) expenses rose 8.6% to $248.4 million [4] - The adjusted operating margin was 30.1%, declining by 100 basis points year-over-year [5] Financial Position - As of September 30, 2025, Mettler-Toledo's cash and cash-equivalent balance was $69.1 million, an increase from $61.8 million as of June 30 [6] - Long-term debt stood at $2.15 billion, with cash generated from operating activities amounting to $299.4 million and free cash flow at $280.7 million for the quarter [6] Future Guidance - For Q4 2025, Mettler-Toledo anticipates a sales increase of approximately 3% in local currency year-over-year, with adjusted earnings projected between $12.68 and $12.88 per share, reflecting a growth rate of 2% to 4% [7] - For the full year 2025, the company expects local currency sales to increase by about 2% over 2024, with adjusted earnings between $42.05 and $42.25 per share, indicating 2-3% growth [9] - Looking ahead to 2026, Mettler-Toledo forecasts a 4% increase in local currency sales over 2025, with adjusted earnings projected between $45.35 and $46.00 per share, representing an 8-9% growth [9]

Financial Performance - Net sales for the three months ended September 30, 2025, were $1.03 billion, an increase of 8% compared to $954.5 million in the same period of 2024[110] - For the nine months ended September 30, 2025, net sales reached $2.90 billion, up 2% from $2.83 billion in 2024[110] - Net sales in the Americas increased by 10% in U.S. dollars for the three months ended September 30, 2025[113] - Service revenue increased by 10% in U.S. dollars for the three months ended September 30, 2025, benefiting from acquisitions[115] - Net sales of laboratory products, representing 55% of total net sales, increased by 6% in U.S. dollars for the three months ended September 30, 2025[116] - Industrial products and services net sales increased by 11% in U.S. dollars for the three months ended September 30, 2025[117] - U.S. Operations reported net sales of $421.6 million in Q3 2025, a 9% increase from $388.5 million in Q3 2024, with net sales to external customers rising 10%[134] - Swiss Operations saw a 12% increase in segment net sales to $270.7 million in Q3 2025, while net sales to external customers decreased by 3%[136] - Western European Operations achieved a 14% increase in segment net sales to $279.2 million in Q3 2025, with net sales to external customers rising 13%[140] - Chinese Operations reported a 5% increase in segment net sales for Q3 2025, with net sales to external customers increasing by 2%[145] - Segment net sales increased by 10% in U.S. dollars for the three months ended September 30, 2025, and by 7% for the nine months ended September 30, 2025, compared to the same periods in 2024[150] - Net sales to external customers rose by 8% in U.S. dollars for the three months ended September 30, 2025, and by 5% for the nine months ended September 30, 2025, compared to the corresponding periods in 2024[150] Profitability and Expenses - Gross profit margin for the three months ended September 30, 2025, was 59.2%, down from 60.0% in 2024, primarily due to increased tariff costs[120] - Research and development expenses increased by 9% in U.S. dollars for the three months ended September 30, 2025, totaling $51.1 million[124] - Selling, general and administrative expenses rose by 9% in U.S. dollars for the three months ended September 30, 2025, amounting to $248.4 million[125] - Amortization expense for Q3 2025 was $20.0 million, up from $18.2 million in Q3 2024, and for the nine months ended September 30, 2025, it was $54.8 million compared to $54.6 million in the same period of 2024[126] - Interest expense decreased to $17.7 million in Q3 2025 from $18.6 million in Q3 2024, and for the nine months ended September 30, 2025, it was $51.1 million compared to $56.8 million in 2024[127] - Restructuring charges increased to $6.0 million in Q3 2025 from $2.6 million in Q3 2024, and for the nine months ended September 30, 2025, they were $13.3 million compared to $17.6 million in 2024[128] - The reported tax rate for Q3 2025 was 19.2%, up from 18.3% in Q3 2024, and for the nine months ended September 30, 2025, it was 18.9% compared to 15.5% in 2024[130] - Segment profit for U.S. Operations decreased by $14.3 million for the nine months ended September 30, 2025, compared to the same period in 2024[135] - Segment profit for Western European Operations increased by $13.3 million in Q3 2025 compared to Q3 2024, driven by increased net sales and margin expansion initiatives[142] - Segment profit increased by $5.2 million and $11.0 million for the three and nine months ended September 30, 2025, respectively, compared to the same periods in 2024[151] Cash Flow and Capital Expenditures - Cash provided by operating activities totaled $730.2 million during the nine months ended September 30, 2025, compared to $702.2 million in the same period in 2024[154] - Capital expenditures amounted to $65.6 million for the nine months ended September 30, 2025, compared to $62.6 million in the corresponding period in 2024[155] - The company spent $656.2 million on share repurchases during the nine months ended September 30, 2025, repurchasing 542,416 shares[157] Debt and Borrowings - As of September 30, 2025, total debt was $2.21 billion, with $1.2 billion in long-term debt[159] - The company had $472.4 million of additional borrowings available under its Credit Agreement as of September 30, 2025[160] Other Considerations - The company estimates incurring approximately $50 million in costs due to incremental tariffs in 2025[108] - A 1% strengthening of the Swiss franc against the euro is estimated to reduce earnings before tax by approximately $2.6 million to $2.9 million annually[166] - The company acquired several businesses during the third quarter of 2025, with initial cash payments totaling $72.6 million and potential additional consideration of up to $31.2 million[156]

Core Insights - The eighth China International Import Expo (CIIE) has seen a record number of participating companies, with a significant increase in new exhibitors [1] - The expo serves as a "super connector" between global quality resources and the Chinese market, continuously attracting multinational giants to debut their products [1] - Notable first-time exhibitors include Sherwin-Williams, showcasing a global core paint product lineup, and Mettler-Toledo, known for its precision instruments, which also launched three global first products [1] - The products presented align with China's demand for smart and low-carbon solutions, reflecting the expo's effect of transforming exhibits into commodities and exhibitors into investors [1] - As more companies relocate their headquarters and R&D centers to China, the CIIE is becoming a central hub for multinational companies to deepen their local market engagement and global strategies [1] - Craig Allen, former president of the US-China Business Council, emphasized that China's innovative vitality relies on diversity, and the CIIE is an excellent platform for leveraging global strengths for China [1]

Mettler-Toledo International (NYSE:MTD) Q3 2025 Earnings Call November 07, 2025 08:30 AM ET Company ParticipantsPatrick Kaltenbach - CEOAdam Uhlman - Head of Investor RelationsShawn Vadala - CFOConference Call ParticipantsDan Arias - AnalystJack Slevin - AnalystJosh Waldman - AnalystLuke Sergott - AnalystBrandon Couillard - AnalystMichael Ryskin - AnalystVijay Kumar - AnalystJosh Heinen - AnalystDoug Schenkel - AnalystCasey Woodring - AnalystPatrick Donnelly - AnalystOperatorHello, and thank you for standin ...

Financial Data and Key Metrics Changes - Sales for Q3 2025 were $1.03 billion, reflecting an 8% increase on a reported basis and a 6% increase in local currency, with a 5% increase excluding recent acquisitions [6][9] - Adjusted EPS for the quarter was $11.15, a 9% increase over the prior year, while reported EPS was $10.57 compared to $9.96 in the prior year [8][9] - Gross margin decreased to 59.2%, down 80 basis points primarily due to tariff costs [7] Business Line Data and Key Metrics Changes - Laboratory sales increased by 4%, while industrial sales grew by 9%, with core industrial growing 10% excluding acquisitions [6][7] - Product inspection sales grew by 7%, and food retail sales increased by 5% [6][7] - Service revenue grew by 8%, including a 1% benefit from acquisitions [7] Market Data and Key Metrics Changes - Local currency sales growth by region showed a 10% increase in the Americas, 6% in Europe, and 1% in Asia [6] - Sales in China increased by 2% during the quarter, marking the first growth in the industrial business in over two years [19][49] Company Strategy and Development Direction - The company is focused on capturing growth opportunities in automation, digitalization, and onshoring, while remaining agile amid global trade uncertainties [4][11] - Recent acquisitions aim to enhance North American distribution and expand life science equipment offerings, contributing modestly to sales growth [10][15] - The company continues to invest in innovation and digital capabilities to improve customer insights and productivity [21][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating market uncertainties and highlighted the importance of innovation and operational excellence [4][20] - The outlook for 2026 anticipates local currency sales growth of approximately 4%, with expectations of gradual improvement in market conditions [23][14] - Management noted that while short-term uncertainties persist, the company is well-positioned to gain market share through its innovative portfolio [24][60] Other Important Information - The company expects local currency sales growth of approximately 3% for Q4 2025, with adjusted EPS guidance in the range of $12.68-$12.88 [12][13] - Tariff costs are projected to have a gross headwind of approximately 7% on EPS for Q4 2025 [12][13] Q&A Session Summary Question: Can you provide a breakdown of the 2026 guidance by segment, particularly for industrial? - Management expects low to mid-single digit growth in laboratory and industrial businesses, with modest benefits from recent acquisitions [27] Question: How is the consumer market affecting the PID segment? - Management noted that while the end market remains challenging, recent innovations have been well-received, particularly in the middle market [29] Question: What is the outlook for onshoring demand? - Management believes the company is well-positioned to benefit from onshoring activities, but expects a gradual impact over the coming years [44] Question: What are the expectations for growth in China? - Management anticipates low single-digit growth in both lab and industrial segments in China for the upcoming year [48] Question: Can you elaborate on the recent acquisitions? - The company completed several small acquisitions to enhance distribution and service capabilities, contributing less than 1% to sales growth [53][54]

Financial Data and Key Metrics Changes - Sales for Q3 2025 were $1.03 billion, reflecting an 8% increase on a reported basis and a 6% increase in local currency, with a 5% increase excluding recent acquisitions [6][10] - Adjusted EPS for the quarter was $11.15, a 9% increase over the prior year, while reported EPS was $10.57 compared to $9.96 in the prior year [9][10] - Gross margin decreased to 59.2%, down 80 basis points primarily due to tariff costs [7][9] - Adjusted operating profit was $309.9 million, up 5% year-over-year, with an adjusted operating margin of 30.1%, a decrease of 100 basis points [8][9] Business Line Data and Key Metrics Changes - Laboratory sales increased by 4%, while industrial sales grew by 9%, with core industrial growing 10% excluding acquisitions [6][8] - Product inspection sales grew by 7%, and food retail sales increased by 5% [6][8] - Service revenue grew by 8%, including a 1% benefit from acquisitions [6][8] Market Data and Key Metrics Changes - Local currency sales growth by region showed a 10% increase in the Americas, 6% in Europe, and 1% in Asia [6][10] - Local currency sales in China increased by 2% during the quarter [6][10] Company Strategy and Development Direction - The company is focused on capturing growth opportunities in automation, digitalization, and onshoring, while remaining agile amid global trade uncertainties [4][12] - Strategic initiatives include investments in innovation and operational excellence to navigate challenging market conditions [4][21] - The company plans to continue using free cash flow primarily for share repurchases and small acquisitions, with an additional $2.75 billion authorized for the share repurchase program [16][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to capture growth despite uncertainties in global trade and governmental policies [4][12] - The outlook for 2026 anticipates local currency sales growth of approximately 4%, with adjusted EPS forecasted to be in the range of $45.35-$46, representing an 8%-9% growth rate [14][15] - Management noted that while market conditions remain challenging, there is potential for gradual improvement and increased replacement demand [23][24] Other Important Information - The company completed several small acquisitions totaling approximately $75 million, which are expected to contribute modestly to sales growth [11][16] - Free cash flow for the first nine months was $689.5 million, a 6% increase on a per-share basis [11] Q&A Session Summary Question: Can you provide a breakdown of the 2026 guidance by segment, particularly around the industrial side? - Management expects low to mid-single digit growth in the laboratory business, with core industrial and product inspection also projected to grow low to mid-single digits [28] Question: How is the consumer market affecting the more consumer-facing segments? - Management noted that while the end market remains challenging, recent product innovations have been well received, particularly in food manufacturing [30] Question: What are the expectations for onshoring demand in 2026 versus 2027? - Management believes the company is well positioned to benefit from onshoring activities, but expects a gradual impact over the coming years [42] Question: What is the outlook for the lab and biopharma side in China? - Management anticipates low single-digit growth in both lab and industrial businesses in China, with some upside potential from recent updates in the Pharmacopia [46] Question: Can you elaborate on the recent acquisitions and their impact? - Management explained that the acquisitions were aimed at expanding distribution and service capabilities, with a focus on enhancing the life science equipment portfolio [52]

Earnings Call Webcast November 7, 2025 Mettler-Toledo International Inc. Q3 2025 Financial Results Safe Harbor Statement 2 Statements in this presentation which are not historical facts constitute "forward looking statements" within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. Securities Exchange Act of 1934. These statements involve known and unknown risks, uncertainties and other factors that may cause our or our businesses, actual results, levels of activity, ...